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Abstract 
Purpose: To investigate the properties of surface-functionalized, hyaluronic acid-coated, cabazitaxel-
loaded solid lipid nanoparticles (HA-CZ-SLNs) for the treatment of breast cancer. 
Methods: HA-CZ-SLNs were prepared by a homogenization method. Nanoparticles were designed for 
prolonged circulation and slow release of the drug, as well as internalization of the nanocarrier into 
cancer cells. The nanoparticles were evaluated using dynamic light scattering, in vitro drug release, cell 
cytotoxicity and uptake studies. 
Results: Transmission electron microscopy revealed the resultant particles to be distinct, discrete, 
spherical cores surrounded by HA shells with a uniform diameter of ~210 nm. In vitro release of CZ 
followed a biphasic pattern with sustained release throughout the study period, implying efficient 
delivery for treatment. Increased cytotoxicity was exerted by HA-CZ-SLNs compared with the free drug. 
More importantly, HA on the surface of nanoparticles interacted with CD44 receptors overexpressed on 
cancer cells, resulting in increased internalization in MCF-7 cells. Excess free HA competed with this 
uptake, indicating that nanoparticle uptake was via receptor-mediated endocytosis. This mechanism is 
expected to result in enhanced therapeutic efficacy for the treatment of breast cancer. 
Conclusion: The results indicate prolonged release and enhanced cell penetration, release and 
cytotoxicity of the drug, thus showing the potential application of the surface-modified nanoparticles for 
the treatment of breast cancer. 
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Invasive breast cancer is the leading cause of 
cancer-related mortality among women 
worldwide [1]. More than 1.8 million cases per 
year are reported in Western countries, 
according to the Federal Research Institute for 
Health Organization and Informatics of the 
Ministry of Health (Russian Federation) and the 
International Agency for Research on Cancer 
[2,3]. Among the various therapies available, 
radiotherapy, surgery, and conventional 
chemotherapy are very effective for the clinical 
treatment of breast cancer [4,5]. Taxanes such 
as docetaxel and paclitaxel have been classified 
as first-line cancer therapy drugs [6,7]. However, 
due to poor survival rates, new drugs have been 
explored to provide more effective therapeutic 
strategies for breast cancer [8]. Cabazitaxel (CZ) 
is a second-generation taxane family member 
specifically designed for the treatment of solid 
tumors. CZ was approved in June 2010 by the 
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US Food and Drug Administration for the 
treatment of cancer [9]. CZ is a hydrophobic drug 
that acts on microtubules, inducing G2/M cell-
cycle arrest, leading to cell death [10,11]. 
However, because of their poor solubility and 
severe side effects, taxanes require modification 
before use in the clinic, and many alternative 
biocompatible formulations have been designed 
to deliver taxane drugs more effectively and 
safely [12]. 
 
Among the various drug-delivery systems, solid 
lipid nanoparticles (SLNs) act as a potent carrier 
system for various pharmaceutical compounds. 
SLNs are considered ideal carrier polymers 
owing to their high biocompatibility and 
bioavailability. Their improved solubility and 
excellent stability result in controlled drug 
release, minimizing adverse effects and 
enhancing antitumor activity [13-15]. Further, 
surface modification of SLNs by site-specific 
targeting agents improves cellular internalization 
and selective targeting. In this context, we have 
used hyaluronic acid (HA), a hydrophilic, anionic, 
biodegradable, nontoxic polymer composed of β-
1,4-D-glucuronic acid-b-1,3-N-acetyl-D-
glucosamine subunits. HA has biological 
properties such as muco-adhesiveness and 
receptor-mediated internalization via CD44 
receptors, which activate some signaling 
pathways. CD44 is an integral membrane 
glycoprotein overexpressed on the cell surfaces 
of several tumor types compared with normal 
cells. These receptors are bound by high-
molecular-weight HA and can be used to target 
cells with high tumorigenic potential [16,17]. 
 
The objective of the present study was to 
develop unique HA-functionalized, CZ-loaded 
SLNs (HA-CZ-SLNs) with high tumor specificity, 
designed to mediate more efficient cellular 
uptake and to facilitate specific tumor-cell 







CZ was supplied by the Shanghai Institute of 
Pharmaceutical Industry  
(Shanghai, China). Didecyldimethylammonium 
bromide (DDAB) and 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma (St. Louis, MO, USA). 
Dulbecco’s Modified Eagle Medium (DMEM) high 
glucose was purchased from HyClone Thermo 
Scientific. (Logan, Waltham, USA) All chemicals 
were analytical grade and used without further 
purification. 
Preparation of HA-CZ-SLNs 
 
HA-CZ-SLNs were prepared by homogenization 
and sonication. Briefly, the lipid phase Compritol 
888 ATO (250 mg), DDAB (30 mg), and CZ (10 
mg) were heated to 5‒10 oC above their melting 
points and melted completely. An aqueous 
solution containing tocopheryl polyethylene 
glycol succinate (TPGS, 100 mg) was preheated, 
added to the lipid phase, and homogenized 
(Ultra-Turrax homogenizer (IKA-Werke, Staufen 
Germany) for 5 min at 12000 rpm. The resulting 
pre-emulsion was probe sonicated for 5 min at 
70 % amplitude [18]. HA and SLN were prepared 
by an electrostatic attraction method, in which 1 
mL of a 0.05 % (w/v) HA solution under vigorous 
stirring was added to a CZ-SLN dispersion at a 
10:1 ratio for 15 min [19]. The final resulting 
suspension was freeze-dried and stored at 4 oC. 
 
Assessments of the particle size (PS), 
polydispersity index (PDI), and zeta potential 
(ZP) 
 
The mean PS, PDI, and ZP of prepared 
nanoparticles diluted in Milli-QTM water were 
measured using an ELSZ-1000 ZP and PS 
analyzer (Photal Otsuka Electronics, Tokyo, 
Japan), based on the dynamic light scattering 
method, at a fixed scattering angle of 90o at 25 





A few drops of the HA-CZ-SLN nanoparticle 
dispersion, diluted 10-fold, were incubated with 2 
% (w/v) phosphotungstic acid for 15 min. The 
sample was subsequently placed on a copper 
grid and dried at ambient temperature. Sample 
grids were examined using TEM to view the 
morphology of nanoparticles. 
 
Encapsulation and loading efficiency 
 
Drug entrapment and loading efficiency were 
calculated from the ratio of the drug entrapped in 
the nanoparticles to the total amount of drug. 
Briefly, drug-loaded complexes were filtered 
using Amicon centrifugal filters at 5000 rpm for 
15 min. The unencapsulated drug (CZ) in the 
filtrate was analyzed by HPLC UV detection at 
280 nm, using a mobile phase of acetonitrile and 
water at a 60:40 ratio and a flow rate of 1 
mL/min. A standard curve was plotted for CZ.  
The encapsulation efficiency (E) and loading 
efficiency (L) were calculated by Equations 1 and 
2, respectively. 
 
E (%) = {(Ct – Cf)/Ct}100………………….(1) 
Zhu & An 
Trop J Pharm Res, June 2017; 16(6): 1385  
 
L (%) = {(Ct – Cf)/W}100………………….(2), 
 
where Ct, Cf, and W are the total amount of CZ, 
the amount of free CZ, and the total weight of the 
nanoparticles, respectively. 
 
In vitro release studies 
 
To evaluate the release of CZ from CZ-SLNs and 
HA-CZ-SLNs, 1 mg/mL of the drug-loaded 
nanoparticles was incubated in 10 mL phosphate 
buffer solution (PBS, pH 7.4, ionic strength 0.1 
M, with 0.2 % Tween 80) in a dialysis bag 
(molecular cut-off of 3.5 kDa) at 37 oC under 
gentle magnetic stirring (100 rpm). At fixed 
intervals, 1 mL of the supernatant was removed 
and replaced with fresh buffer solution to 
maintain a sink condition. CZ released in the 
collected samples was extracted with acetonitrile 
and determined by HPLC as described above. All 




MCF-7 cells were obtained from the American 
Type Culture Collection (Manassas, USA), and 
the cells were cultured in DMEM supplemented 
with 10 % FBS and 5 % penicillin/streptomycin. 
Cells were maintained at 37 °C and 5 % CO2 in a 




Cell viability following treatment with the 
individual formulations was determined by MTT 
assay. Cells (1 × 104) were seeded into 96-well 
plates in 0.1 mL growth medium and incubated 
for 24 h. Cells were then treated with the drug 
formulations (CZ, CZ-SLNs, and HA-CZ-SLNs) at 
0.01‒50 µg/mL or with control formulations 
(SLNs and HA-SLNs) at 0.1‒1000 µg/mL. All 
formulations were incubated for 48 h, washed 
twice with PBS, treated with MTT solution (5 
mg/mL), and incubated for another 3 h. The 
resultant formazan crystals were dissolved in 100 
µL DMSO. The mixture was gently shaken in a 
microplate reader before measuring the 




MCF-7 cells (2 × 105) were seeded in 6-well 
plates and incubated for 24 h at 37 °C. Cultures 
were pretreated with or without HA (100 µL, 1 
mg/mL) for 15 min and further treated with the 
HA-CZ-SLN formulations for 30 min. The cells 
were washed twice with PBS, trypsinized, 
centrifuged, and resuspended in PBS prior to 





All experiments were performed in triplicate, and 
results are presented as mean ± SD. Student’s t-
test was used to compare differences between 
groups, with p < 0.05 considered to indicate 
statistical significance. Statistical evaluation was 
performed using Mann-Whitney U test with the 
aid of SPSS Statistics 20.0 program (SPSS Inc., 




Characteristics of HA-CZ-SLNs 
 
A schematic illustration of the HA-CZ-SLNs 
prepared by a high-pressure homogenization 
method is shown in Figure 1. The solid lipid core 
was prepared with compritol and DDAB 
(Didodecyldimethylammonium bromide), with 
Tween 80 added as a cationic lipid and 
surfactant. These lipids and tocopheryl 
polyethylene glycol succinate TPGS molecules 
were embedded as phospholipid molecules, 
which reduce leakage of the active therapeutic 
moiety from the nanoparticle. A mixture of CZ, 
compritol, DDAB, and TPGS was dissolved in 
ethanol and preheated at 45 °C under 




Figure 1: Schematic illustration of surface-functionalized hyaluronic acid-coated cabazitaxel-loaded solid lipid 
nanoparticles (HA-CZ-SLNs) 
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This emulsion was homogenized for 5 min and 
sonicated at 70 % amplitude for 5 min. Figure 2a 
and Figure 2b show that the average PS of the 
CZ-SLNs was 187.8 ± 3.41 nm, with strong 
positive charges averaging 41.7 ± 2.13 mV and a 
PDI of 0.13, due to the presence of cationic 
lipids. Furthermore, the outer surface of the lipid 
nanoparticle was coated with HA via electrostatic 
interactions, increasing the particle size to 221.6 
± 2.67 nm and converting to a strong negative 
charge: ‒20.7 ± 1.12 mV (Figure 2c and Figure 
2d). 
 
CZ was loaded into the hydrophobic core, and 
the encapsulation efficiency was determined by 
HPLC at 72.31 ± 2.41 %, with a loading capacity 
of 4.41 ± 1.41 %. Lastly, the particles were 
freeze-dried and stored at 4oC. The morphology 
of the optimized HA-CZ-SLNs was revealed by 




Figure 3: TEM image of the HA-CZ-SLNs 
 
These images represent narrow spherical 
particles, with compact cores. The shell 
structures were observed as a layer on the core 
after coating the surfaces with HA, consistent 
with the dynamic light scattering data. 
 
In vitro drug release 
 
The in vitro release profile of CZ from CZ-SLN 
and HA-CZ-SLN formulations was examined by 
dialysis. As illustrated in Figure 4, release from 
CZ-SLNs followed a biphasic pattern, with an 
initial burst release of 42 % within 8 h, followed 
by a sustained release of 65 % over 48 h. HA-
CZ-SLNs followed a monophasic release pattern, 
with approximately 31.4 and 42 % released by 12 
and 48 h, respectively. The burst release was 
due to the loose association between the drug 
and lipid, and the drug loaded into the core 
underwent further sustained release. In the case 
of HA-CZ-SLNs, the slower release rate was due 
to incorporation of CZ into the inner core of SLN, 
protected by the exterior HA layer on the surface, 
which acts as a barrier to enable sustained and 




The effects of the different formulations on cell 
viability were investigated in MCF-7 cells by MTT 
assay (Figure 5). The drug-free SLNs and HA-
SLNs at concentrations of 0.1‒1000 µg/mL 
showed acceptable cell viability of 85 % after 24 
h of exposure, indicating that the carrier has 
excellent biocompatibility. 
 
Figure 2: Dynamic light scattering characterization of particle size (a, b) and zeta potential (c, d) of CZ-SLNs and 
HA-CZ-SLNs, respectively 
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Figure 4: In vitro release study of CZ-SLNs and HA-
CZ-SLNs, respectively, in PBS 
 
Treatment with 1 µg/mL HA-CZ-SLNs exhibited 
significantly higher toxicity, with only 45 % cell 
viability after treatment, compared with 68 % 
viability after treatment with free CZ. This 
indicates enhanced internalization by CD44 
receptor-mediated endocytosis and subsequent 
induction of apoptosis. These data further 
indicate that HA-CZ-SLNs are more effective in 
inducing cell toxicity, even at higher 
concentrations of the free drug. 
 
Cellular uptake  
 
The internalization of HA-CZ-SLNs was 
evaluated in MCF-7 cells by flow cytometry 
(Figure 7). The results clearly demonstrate 
increased uptake of HA-CZ-SLNs compared with 
the controls, due to the interaction of HA with 
CD44. In addition, cells pre-treated with excess 
free HA for 1 h before exposure to HA-CZ-SLNs 
showed slightly reduced intracellular fluores-
cence intensity. 
 
Figure 5: In vitro cytotoxicity of free CZ, CZ-SLNs, and HA-CZ-SLNs after incubation for 24 h (n = 6) 
 
 
Figure 6: In vitro cytotoxicity of control SLNs and HA-SLNs at various concentrations after incubation for 24 h (n 
= 6) 
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Figure 7: Intracellular uptake of HA-CZ-SLNs and the effects of 1 h pre-treatment with excess HA in CD44-
overexpressing MCF-7 cells 
 
These results indicated significantly higher 
uptake of HA-CZ-SLNs, which were bound to the 
overexpressed CD44 receptors on MCF-7 cells 
and internalized via receptor-mediated 
endocytosis. This was remarkably diminished 
after HA pretreatment, independent of the charge 




CZ, which has been approved by the U.S. Food 
and Drug Administration, is used clinically at 
various dilutions for intravenous administration. 
CZ has the advantage of overcoming multidrug 
resistance due to its poor affinity, compared with 
other taxane members such as docetaxel and 
paclitaxel, for P-glycoprotein, which pumps 
intracellular drugs out of cells [9]. However, there 
are drug stability problems with CZ, as well as 
adverse effects, especially neutropenia. 
Therefore, biocompatible nanosystems, such as 
SLNs, have been designed to improve the 
delivery of CZ, with enhanced permeability and 
retention effects and the ability to target tumors 
by CD44 receptor-mediated endocytosis of HA. 
Compared with other nano-delivery systems, 
SLNs exhibit many advantages, including easier 
preparation, improved stability, and component 
material safety. Hence, we developed surface-
modified CZ-loaded SLNs for the treatment of 
breast cancer. Coating the SLNs with HA led to 
significantly greater accumulation in tumor-
bearing lung tissue than was seen with uncoated 
SLNs. Coating by electrostatic attraction is a 
simple and controllable method that precludes 
using the chemical reactions and organic 
solvents needed to attach HA covalently to 
nanoparticles. Due to the high tumor specificity 
and biocompatibility properties of high-molecular-
weight HA, we designed optimized HA-CZ-SLNs 
that mediated more efficient cellular uptake and 
facilitated delivery of anticancer drugs such as 
CZ to specific tumor cells (CD44+). 
 
The rate of drug release from CZ-SLNs follows a 
biphasic pattern, with an initial burst release 
followed by sustained release, whereas that from 
HA-CZ-SLNs follows a monophasic release 
pattern. The burst release pattern is the result of 
the drug loaded loosely into the lipid, and further 
sustained release is the result of the drug loaded 
into the core. The toxicity of the drug-free carrier 
is negligible because of its highly biocompatible 
nature. The observed 20 % carrier toxicity is 
caused by the cationic lipid, which promotes cell 
degradation. In addition, the cytotoxic effects of 
various formulations, such as free CZ, CZ-SLN, 
and HA-CZ-SLNs, exhibited a typical 
concentration-dependent cytotoxicity after 24 h of 
incubation. Drug-containing particles showed 
enhanced cellular CZ retention and intracellular 
acid-responsive drug release, resulting in 
disruption of β-tubulin in the G2/M phase, cell 
death via apoptosis, and enhanced cytotoxicity 
[19]. Increased uptake of HA-CZ-SLNs compared 
with control preparations was caused by the 
interaction of HA with CD44. Cells pre-treated 
with excess free HA for 1 h before HA-CZ-SLN 
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treatment showed slightly reduced intracellular 
fluorescence intensity. These results indicate that 
the significantly higher uptake of HA-CZ-SLNs 
was caused by binding of the overexpressed 
CD44 receptors on MCF-7 cells and to receptor-
mediated endocytosis, which could be inhibited 
by binding competition by free HA, independent 




Surface-functionalized CZ-loaded lipid 
nanoparticles for breast cancer therapy have 
been prepared using HA. The in vitro profiles 
indicate sustained release of the nanoparticles. 
In addition, the encapsulated CZ show higher 
cytotoxicity against MCF-7 cells than did free CZ. 
The significantly increased internalization 
observed is the result of the HA layer that 
interacted with the CD44 receptor overexpressed 
on cancer cells. Thus, HA-CZ-SLNs are an 
excellent lipid-based formulation with enhanced 
antitumor activity and hence a potential 
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